The FDA lifted a clinical hold on Intellia’s Magnitude‑2 Phase 3 trial of its in vivo CRISPR therapy nexiguran ziclumeran (nex‑z) for transthyretin amyloidosis with polyneuropathy (ATTR‑PN) while keeping a parallel cardiomyopathy study on hold. Intellia said the agency’s decision follows safety reviews tied to severe liver transaminase elevations and a prior patient death in the cardiomyopathy arm; the company implemented additional safety measures and monitoring. Resuming Magnitude‑2 lets Intellia continue an important pathway toward regulatory approval for the neuropathy indication while it works with the FDA on risk‑mitigation for the cardiac population. The partial lift improved investor sentiment for Intellia, though analysts flagged lingering regulatory uncertainty and the need for robust hepatic safety data before the broader program can proceed.